A prospective clinical trial validating our DELFI AI blood test for early detection of lung cancer has just been published in Cancer Discovery. As the first validated blood test for detecting lung cancer, this cell-free DNA fragmentome assay has the potential to make lung cancer less invasive, more accessible and to save lives from the leading cause of cancer deaths. Congratulations to team members at Johns Hopkins, collaborators at multiple institutions, and DELFI!
Mazzone PJ, Bach PB, Carey J, Schonewolf CA, Bognar K, Ahluwalia MS, Cruz-Correa M, Gierada D, Kotagiri S, Lloyd K, Maldonado F, Ortendahl JD, Sequist LV, Silvestri GA, Tanner N, Thompson JC, Vachani A, Wong KK, Zaidi AH, Catallini J, Gershman A, Lumbard K, Millberg LK, Nawrocki J, Portwood C, Rangnekar A, Sheridan CC, Trivedi N, Wu T, Zong Y, Cotton L, Ryan A, Cisar C, Leal A, Dracopoli NC, Scharpf RB, Velculescu VE, Pike LRG. Clinical validation of a cell-free DNA fragmentome assay for augmentation of lung cancer early detection. Cancer Discovery. 2024 Nov 1;14(11):2224-2242. doi: 10.1158/2159-8290.CD-24-0519. PMID: 38829053. Article | Press
